SaaS entity
All 1 tracked stories fall under one category: earnings. Evolent is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Their average consequence score of 5 runs below the beat's 6.2 for that window. Each story carries 2 original sources on average, compared with 2.1 for the broader beat in this window.
Last mentioned: Feb 24, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: earnings. Evolent is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Their average consequence score of 5 runs below the beat's 6.2 for that window. Each story carries 2 original sources on average, compared with 2.1 for the broader beat in this window. We currently track 1 SaaS story that mention CyTOF, all published on February 24, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 25 SaaS stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering CyTOF. Shared-story counts are live from our verified record — not editorial picks.
Evolent and Standard BioTools reported strong 2025 revenue growth, with Evolent crossing the $2.6 billion threshold and Standard BioTools achieving its first positive adjusted EBITDA quarter. Both companies are now pivoting toward margin expansion and operational discipline as they enter the 2026 fiscal year.
CyTOF is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
